|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||206.32 - 210.89|
|52 Week Range||117.06 - 218.00|
|Beta (5Y Monthly)||0.28|
|PE Ratio (TTM)||30.49|
|Earnings Date||Apr 27, 2021|
|Forward Dividend & Yield||3.40 (1.64%)|
|Ex-Dividend Date||Feb 11, 2021|
|1y Target Est||216.14|
Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and license agreement that will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.
Top Research Reports for Eli Lilly, McDonald's & TOTAL
Merck (MRK) announces encouraging preliminary data from a mid-stage study evaluating its oral COVID-19 antiviral candidate, molnupiravir, evaluating it in non-hospitalized adults with symptomatic COVID-19.